Huang Y, Chen Z, Deng W, Jiang Y, Pan Y, Yuan Z
Cell Death Dis. 2025; 16(1):173.
PMID: 40075073
PMC: 11903874.
DOI: 10.1038/s41419-025-07472-9.
Tio M, Wen R, Choo C, Tan J, Chua A, Xiao B
J Biomed Sci. 2024; 31(1):24.
PMID: 38395904
PMC: 10893700.
DOI: 10.1186/s12929-024-01010-z.
Liu X, Wang F, Fan X, Chen M, Xu X, Xu Q
Cell Death Dis. 2024; 15(2):126.
PMID: 38341417
PMC: 10858906.
DOI: 10.1038/s41419-024-06523-x.
Kim J, Kwon E, Kim Y, Kim D, Shin Y, Gil D
Cell Mol Life Sci. 2024; 81(1):38.
PMID: 38214772
PMC: 10787008.
DOI: 10.1007/s00018-023-05060-8.
Choong C, Mochizuki H
Int J Mol Sci. 2023; 24(23).
PMID: 38069350
PMC: 10707101.
DOI: 10.3390/ijms242317027.
Mitochondria, a Key Target in Amyotrophic Lateral Sclerosis Pathogenesis.
Genin E, Abou-Ali M, Paquis-Flucklinger V
Genes (Basel). 2023; 14(11).
PMID: 38002924
PMC: 10671245.
DOI: 10.3390/genes14111981.
CHCHD2 mediates glioblastoma cell proliferation, mitochondrial metabolism, hypoxia‑induced invasion and therapeutic resistance.
Lumibao J, Haak P, Kolossov V, Chen J, Stutchman J, Ruiz A
Int J Oncol. 2023; 63(5).
PMID: 37654190
PMC: 10546377.
DOI: 10.3892/ijo.2023.5565.
Involvement of casein kinase 1 epsilon/delta (Csnk1e/d) in the pathogenesis of familial Parkinson's disease caused by CHCHD2.
Torii S, Arakawa S, Sato S, Ishikawa K, Taniguchi D, Sakurai H
EMBO Mol Med. 2023; 15(9):e17451.
PMID: 37578019
PMC: 10493588.
DOI: 10.15252/emmm.202317451.
The MNRR1 activator nitazoxanide abrogates lipopolysaccharide-induced preterm birth in mice.
Purandare N, Gomez-Lopez N, Arenas-Hernandez M, Galaz J, Romero R, Xi Y
Placenta. 2023; 140:66-71.
PMID: 37544161
PMC: 10529525.
DOI: 10.1016/j.placenta.2023.07.005.
CHCHD2 Thr61Ile mutation impairs F1F0-ATPase assembly in and models of Parkinson's disease.
Chen X, Lin Y, Zhang Z, Tang Y, Ye P, Dai W
Neural Regen Res. 2023; 19(1):196-204.
PMID: 37488867
PMC: 10479855.
DOI: 10.4103/1673-5374.378010.
Clinical chorioamnionitis at term is characterized by changes in the plasma concentration of CHCHD2/MNRR1, a mitochondrial protein.
Bosco M, Romero R, Gallo D, Suksai M, Gotsch F, Jung E
J Matern Fetal Neonatal Med. 2023; 36(2):2222333.
PMID: 37349086
PMC: 10445405.
DOI: 10.1080/14767058.2023.2222333.
What is the role of CHCHD2 in adrenal tumourigenesis?.
Karapanagioti A, Nasiri-Ansari N, Moustogiannis A, Trigas G, Zografos G, Aggeli C
Endocrine. 2023; 81(2):357-367.
PMID: 37221428
DOI: 10.1007/s12020-023-03393-9.
Evidence for the participation of CHCHD2/MNRR1, a mitochondrial protein, in spontaneous labor at term and in preterm labor with intra-amniotic infection.
Bosco M, Romero R, Gallo D, Suksai M, Gotsch F, Jung E
J Matern Fetal Neonatal Med. 2023; 36(1):2183088.
PMID: 36941246
PMC: 10352953.
DOI: 10.1080/14767058.2023.2183088.
Increased CHCHD2 expression promotes liver fibrosis in nonalcoholic steatohepatitis via Notch/osteopontin signaling.
Li Y, Xiu W, Xu J, Chen X, Wang G, Duan J
JCI Insight. 2022; 7(23).
PMID: 36477358
PMC: 9746920.
DOI: 10.1172/jci.insight.162402.
Lipopolysaccharide induces placental mitochondrial dysfunction in murine and human systems by reducing MNRR1 levels via a TLR4-independent pathway.
Purandare N, Kunji Y, Xi Y, Romero R, Gomez-Lopez N, Fribley A
iScience. 2022; 25(11):105342.
PMID: 36339251
PMC: 9633742.
DOI: 10.1016/j.isci.2022.105342.
CHCHD2 p.Thr61Ile knock-in mice exhibit motor defects and neuropathological features of Parkinson's disease.
Fan L, Zhang S, Li X, Hu Z, Yang J, Zhang S
Brain Pathol. 2022; 33(3):e13124.
PMID: 36322611
PMC: 10154378.
DOI: 10.1111/bpa.13124.
CHCHD2 and CHCHD10: Future therapeutic targets in cognitive disorder and motor neuron disorder.
Jiang T, Wang Y, Wang X, Xu J
Front Neurosci. 2022; 16:988265.
PMID: 36061599
PMC: 9434015.
DOI: 10.3389/fnins.2022.988265.
CHCHD2 maintains mitochondrial contact site and cristae organizing system stability and protects against mitochondrial dysfunction in an experimental model of Parkinson's disease.
Lu L, Mao H, Zhou M, Lin Y, Dai W, Qiu J
Chin Med J (Engl). 2022; .
PMID: 35830185
PMC: 9532036.
DOI: 10.1097/CM9.0000000000002053.
Pathological characterization of a novel mouse model expressing the PD-linked CHCHD2-T61I mutation.
Kee T, Wehinger J, Espinoza Gonzalez P, Nguyen E, McGill Percy K, Khan S
Hum Mol Genet. 2022; 31(23):3987-4005.
PMID: 35786718
PMC: 9703812.
DOI: 10.1093/hmg/ddac083.
The Prognostic Signature of Head and Neck Squamous Cell Carcinoma Constructed by Immune-Related RNA-Binding Proteins.
Ming R, Li X, Wang E, Wei J, Liu B, Zhou P
Front Oncol. 2022; 12:795781.
PMID: 35449571
PMC: 9016149.
DOI: 10.3389/fonc.2022.795781.